<DOC>
	<DOCNO>NCT01849744</DOCNO>
	<brief_summary>This Phase I , open-label , multicenter , dose-escalation trial VS-4718 , focal adhesion kinase inhibitor , subject metastatic non-hematologic malignancy . This clinical study comprise 2 part : Part 1 ( Dose Escalation ) Part 2 ( Expansion ) . The purpose study evaluate safety ( include recommend Phase II dose ) , pharmacokinetics ( amount VS-4718 blood ) anti-cancer activity VS-4718 . The pharmacodynamic effect ( gene protein may predict show body may respond VS-4718 ) also examine tumor biopsy blood sample .</brief_summary>
	<brief_title>Phase I Dose Escalation Study VS-4718 Subjects With Metastatic Non-Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Age ≥ 18 year . Histopathologically confirm diagnosis metastatic nonhematologic malignancy . ECOG ( Eastern Cooperative Oncology Group ) performance status ≤ 2 Adequate renal function Adequate hepatic function ( total bilirubin ≤ 1.5x ULN ( upper limit normal ) institution ; AST [ aspartate transaminase ] ALT [ alanine transaminase ] ≤ 3x ULN , ≤ 5x ULN due liver involvement tumor ) . Adequate bone marrow function ( hemoglobin ≥ 9.0 g/dL ; unsupported platelet ≥ 100 x10 9 cells/L ; absolute neutrophil count ≥ 1.5x10 9 cells/L Corrected QT interval ( QTc ) &lt; 470 ms Subjects must least one tumor lesion suitable repeat biopsy , must agree two tumor biopsy ( pre post treatment ) . Willing able participate trial comply trial requirement . Gastrointestinal ( GI ) condition could interfere swallow absorption study medication . Uncontrolled severe concurrent medical condition ( include uncontrolled brain metastasis ) . History upper gastrointestinal bleeding , ulceration , perforation within 12 month . Known history stroke cerebrovascular accident within 6 month . Subjects actively treat secondary malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Focal Adhesion Kinase inhibitor</keyword>
	<keyword>FAK inhibitor</keyword>
	<keyword>Cancer Stem Cells</keyword>
	<keyword>CSC</keyword>
</DOC>